American Journal of Hematology最新文献

A Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis. 达拉单抗、伊唑唑米和地塞米松治疗AL淀粉样变性的1期研究

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-06-01 Epub Date: 2026-02-19 DOI: 10.1002/ajh.70239

Hans C Lee, Melody R Becnel, Lei Feng, Oren Pasvolsky, Astrid Murga, Ralph J Johnson, Sheeba K Thomas, Qaiser Bashir, Muzaffar H Qazilbash, Raphael Steiner, Swaminathan P Iyer, Donna M Weber, Krina K Patel, Gregory P Kaufman, Elisabet E Manasanch, Robert Z Orlowski

引用次数: 0

Late Onset Telomere Biology Disorder Presenting With Pancytopenia, Immune Dysregulation, Interstitial Lung Disease and Alopecia. 迟发性端粒生物学紊乱，表现为全血细胞减少、免疫失调、间质性肺疾病和脱发。

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-06-01 Epub Date: 2026-02-24 DOI: 10.1002/ajh.70234

Bo A Wan, Hamish Nicolson, Heather A Leitch, Ryan J Stubbins, Luke Y C Chen, Timothy Murray, Amy Trottier, Anthony Gador

引用次数: 0

Diagnosis and Management of Acute Chest Syndrome in Children With Sickle Cell Disease. 镰状细胞病患儿急性胸综合征的诊断与治疗

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-06-01 Epub Date: 2026-02-27 DOI: 10.1002/ajh.70260

Thomas C Fisher-Heath, Colin Rogerson, Benjamin Nti, Patrick T McGann, Matthew Hays, Seethal A Jacob

引用次数: 0

Minutes Matter: An Audit of the Timeliness of Opioid Administration for Sickle Cell Disease Pain in the Emergency Department and Association With Disposition. 分钟事项：对急诊科镰状细胞病疼痛阿片类药物管理及时性的审计及其与处置的关联。

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-06-01 Epub Date: 2026-02-26 DOI: 10.1002/ajh.70253

Ibrahim Gwarzo, Harish Chandra Dega, David C Brousseau

引用次数: 0

Feasibility and Characteristics of Systematic Transcranial Doppler in Adults With Sickle Cell Disease: A Cross-Sectional Single Center Study. 成人镰状细胞病系统经颅多普勒的可行性和特点：一项横断面单中心研究。

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-06-01 Epub Date: 2026-02-25 DOI: 10.1002/ajh.70252

Olivier Pouliot, Costa Kazadi, Chrystelle Charles, Jonathan St-Onge, Olena Bereznyakova, Marie-Andrée Panzini, Julian Rivillas, Christian Stapf, Gregory Jacquin, Stéphanie Forté

引用次数: 0

Decreased Chronic GvHD With Post-Transplant Cyclophosphamide Versus ATG in Patients With Myelofibrosis Allografted With an Unrelated Donor: A Study From the Chronic Malignancies Working Party of the EBMT. 来自EBMT慢性恶性肿瘤工作组的一项研究：非亲属骨髓纤维化同种异体移植患者移植后使用环磷酰胺与ATG降低慢性GvHD

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-06-01 Epub Date: 2026-03-20 DOI: 10.1002/ajh.70288

Yves Chalandon, Edouard F Bonneville, Diderik-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Joe Tuffnell, Jakob Passweg, Johannes Schetelig, Uwe Platzbecker, Ibrahim Yakoub-Agha, Urpu Salmenniemi, Mareike Verbeek, Moniek A de Witte, Jean-Baptiste Méar, John A Snowden, Tobias A W Holderried, Gwendolyn van Gorkom, Frédéric Baron, Marie Robin, Xavier Poiré, Mieke W H Roeven, Maija Itälä-Remes, Jan Zaucha, Kavita Raj, Joanna Drozd-Sokolowska, Giorgia Battipaglia, Tomasz Czerw, Juan Carlos Hernández-Boluda, Nicola Polverelli, Donal P McLornan

引用次数: 0

Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management. 边缘带淋巴瘤：2026诊断和管理的最新进展。

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-06-01 Epub Date: 2026-03-23 DOI: 10.1002/ajh.70289

Wan Danial Noor, John F Seymour, Chan Yoon Cheah

{"title":"Marginal Zone Lymphoma: 2026 Update on Diagnosis and Management.","authors":"Wan Danial Noor, John F Seymour, Chan Yoon Cheah","doi":"10.1002/ajh.70289","DOIUrl":"10.1002/ajh.70289","url":null,"abstract":"Disease overview: Marginal zone lymphoma (MZL) is a heterogeneous group of indolent mature B-cell neoplasms with classically three major subtypes: nodal, splenic, and extranodal MZL of mucosa-associated lymphoid tissue (MALT).Diagnosis: Diagnosis and disease evaluation of MZL is further advanced by the use of genomic testing and PET/CT with emerging evidence for the use of circulating tumor DNA. The RECLASS classification system proposed a hierarchical approach to classifying MZL while the FIL-NF10 investigators introduced a fourth MZL subtype, disseminated MZL. Though the prognosis of MZL varies between subtypes and stages, the MZL IPI and FLIPI24 indices can be used for prognostication.Treatment: Frontline treatment of MZL varies between localized disease and advanced-stage diseases. The former favor the use of local therapies such as radiotherapy and anti-microbial in certain subtypes with a selective role of rituximab monotherapy. The latter requires systemic immunotherapy ± chemotherapy with emerging data for cytotoxic-free and covalent Bruton tyrosine kinase inhibitor (cBTKi)-based regimens. cBTKi and immunomodulators are established in relapsed/refractory MZL, while data for antibody-drug conjugates, T-cell engagers, and potentially CAR T-cell therapies are maturing.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":"1320-1340"},"PeriodicalIF":9.9,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147497316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-World Usage and Outcomes of Different Siltuximab Dosing Frequency in Idiopathic Multicentric Castleman Disease. 不同西妥昔单抗给药频率在特发性多中心Castleman病中的实际应用和结果

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-05-08 DOI: 10.1002/ajh.70352

Yoshito Nishimura, Maria Santiago Estevez, Hakeem Asad, Thomas Habermann, Angela Dispenzieri

引用次数: 0

Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis. CAR - t细胞治疗后的噬血细胞淋巴组织细胞增多症：一项系统综述和荟萃分析。

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-05-05 DOI: 10.1002/ajh.70351

Changhui Zhang, Hongyan Wu, Tiantian Cao, Chaoling Wu, Changjian Yan, Wenxin Qi, Yuqi Zhang, Xingzhao Ji, Hongmei Jing, Qin Peng, Weilong Zhang

{"title":"Hemophagocytic Lymphohistiocytosis After CAR T-Cell Therapy: A Systematic Review and Meta-Analysis.","authors":"Changhui Zhang, Hongyan Wu, Tiantian Cao, Chaoling Wu, Changjian Yan, Wenxin Qi, Yuqi Zhang, Xingzhao Ji, Hongmei Jing, Qin Peng, Weilong Zhang","doi":"10.1002/ajh.70351","DOIUrl":"https://doi.org/10.1002/ajh.70351","url":null,"abstract":"Chimeric Antigen Receptor T-cell Immunotherapy represents a breakthrough in treating relapsed/refractory hematologic malignancies, yet immune-related adverse events, particularly hemophagocytic lymphohistiocytosis (HLH), also known as immune effector cell-associated HLH-like syndrome (IEC-HS), are rapid-progressing and life-threatening. This systematic review and meta-analysis searched PubMed, Embase, and Cochrane CENTRAL up to August 20, 2025. Nineteen studies were analyzed using a random-effects model, covering 2780 patients, 47 HLH cases, and 20 HLH-related deaths. The pooled incidence of HLH was 1.6% at a median follow-up of 12.9 months, with an associated HLH mortality of 0.7%. The incidence of HLH differed markedly by disease entity (p = 0.0008), highest in B-cell acute lymphoblastic leukemia (B-ALL: 6.9%). CAR T-cell product was also a significant determinant (p = 0.0036), with tisagenlecleucel (Tisa-cel) showing the highest incidence (4.3%). Subgroup analyses confirmed that Tisa-cel had a significantly higher HLH incidence than axicabtagene ciloleucel (Axi-cel) in large B-cell lymphoma (2.4% vs. 0.6%, p = 0.038), and ciltacabtagene autoleucel (Cilta-cel) had a higher incidence than idecabtagene vicleucel (Ide-cel) in multiple myeloma (2.6% vs. 0.7%, p = 0.022). Higher-grade cytokine release syndrome (CRS) was positively correlated with HLH incidence, particularly in MM. Overall HLH incidence was significantly positively correlated with mortality. In conclusion, HLH risk after CAR T-cell therapy is primarily driven by underlying disease type and specific CAR T-cell product, with additional contribution from severe CRS. Enhanced surveillance and early intervention are strongly recommended for high-risk groups, particularly B-ALL patients and recipients of Tisa-cel or Cilta-cel.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147832707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse. 套细胞淋巴瘤CAR-T后可测量的残留疾病监测能够早期发现疾病复发。

IF 9.9 1区医学

American Journal of Hematology Pub Date : 2026-05-04 DOI: 10.1002/ajh.70343

Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen-Kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J Frank

{"title":"Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.","authors":"Snegha Ananth, Neha Agarwal, Bita Sahaf, Allison Jacob, Lik Wee Lee, Heidi Simmons, Ilan Kirsch, Sushma Bharadwaj, Wen-Kai Weng, Melody Smith, Saurabh Dahiya, David Miklos, Matthew J Frank","doi":"10.1002/ajh.70343","DOIUrl":"https://doi.org/10.1002/ajh.70343","url":null,"abstract":"CD19-directed chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for patients with relapsed or refractory (r/r) mantle cell lymphoma (MCL), yet more than 40% relapse within one year. Early identification of patients at risk for progression could inform post CAR-T surveillance and consolidation strategies. Measurable residual disease (MRD) has emerged as a powerful prognostic biomarker in frontline MCL, but its role after CAR T-cell therapy remains incompletely defined. We retrospectively analyzed 37 patients with r/r MCL treated with brexucabtagene autoleucel (brexu-cel). MRD was assessed using next-generation immunoglobulin high-throughput sequencing (Ig-HTS) of peripheral blood mononuclear cells obtained before lymphodepletion, at 1- and 3-months post-infusion, and every 3 months thereafter. Clonotype identification was successful in 36 of 37 patients. Pre-lymphodepletion MRD levels were lower in patients receiving bridging therapy (337 [0-198 449] vs. 21 213 [1-788 251]; p = 0.04), and MRD undetectability trended toward improved progression-free survival (PFS; unreached vs. 28.5 months; HR 5.2; p = 0.07). Post-infusion, patients with detectable Day 28 MRD had inferior PFS compared with those with undetectable MRD (10.9 vs. 51.5 months; HR 3.99; p = 0.002), whereas Day 28 PET-CT response did not correlate with PFS (p = 0.35; HR 1.8). Longitudinal MRD monitoring identified relapse a median of 6.5 months before PET/CT in most relapsing patients (15 out of 18). Early and serial MRD monitoring is thus a sensitive prognostic and surveillance tool in brexu-cel treated MCL, with Day 28 MRD serving as an early predictor of long-term outcomes.","PeriodicalId":7724,"journal":{"name":"American Journal of Hematology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0